Oncothermia Journal
Volume 3

Download the full journal

Jing-Hong L (2011) Electrochemical Therapy of Tumors. Oncothermia Journal 3:12-33

“What is Electrochemical Therapy(EChT) Inserting electrodes (special produced by platinum) into tumor and connecting its with EChT apparatus, direct electric current arouse strong chemical reactions around electrodes and lead degeneration and necrosis of tumor cells. It is a new type method to treat tumor without surgical resection. The final result is caused by direct electric current inducing chemical reactions, so it is called EChT….”

Pang LKC (2011) Status and Prospect on Contemporary Natural Medicine. Oncothermia Journal 3:35-38

“1. Concept of Natural Medicine

Natural Medicine has evolved along with human social evolution. It started by using primitive natural methods, natural medication and traditional health preservation methods, for disease diagnosis and treatment, rehabilitation, disease prevention, and health maintenance. Now, Natural Medicine has become an encompassing discipline of the medical field. However, the basic concept of Natural Medicine remains “human and nature in unison,” “mind and body in unison,” that is, the harmonious whole-body concept….”

Dani A, Varkonyi A, Magyar T, Szasz A (2011) Clinical study for advanced non-small-cell lung cancer treated by oncothermia. Oncothermia Journal 3:40-49


The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both of the centers and make a metaanalysis as well. Results show a remarkable survival benefit for the patients compared to the historical data. The comparison of the studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and greatly points out the feasibility of the oncothermia application on the NSCLC….”


Yoon SM, Lee JS (2011) A Case of Abscopal effect with Metastatic Non-Small-Cell Lung Cancer treated with Radiation therapy and Oncothermia. Oncothermia Journal 3:51-51


During the last decade, there has been an amazing progress in cancer research and treatment in the world and also in Korea. Nevertheless, the overall 5-year survival rate of lung cancer patients in 2001-2005 period was still 15,6% in South Korea. This type of cancer is usually diagnosed in advanced stage, consequently the overall survival did not show noticeable improvement….”

Andocs G, Balogh L, Meggyeshazi N, Jakab Cs, Krenacs T, Szasz A (2011) Apoptosis induction with modulated radiofrequency (RF) hyperthermia (oncothermia) in immune-defficient mice xenograft tumors (Review). Oncothermia Journal 3:52-52

“Introduction – objective of the work

Oncothermia method is more than twenty years serving the medical practice. It has successful applications ether as monotherapy, when no other possibility could be applied. The specialized animal-experiments had been started five years ago intending to clarify the basic mechanisms by in vivo scientific approaches. The complexity and interdisciplinary of the in vivo experimental series requested a wide cooperative scheme of various respected and honored research institutes and university laboratories. Our objective is to summarize the results of this intensive work and show the conclusions at the recent phase of the investigations….”

Szasz N, Andocs G, Szasz O, Balogh L, Muller L, Meggyeshazi N, Szasz A (2011) Are we able igniting natural processes to kill cancer cells? Oncothermia Journal 3:53-53

“Long-time living ancient paradigm is eliminating the tumor cells by drastic, artificial effects (resection and necrosis) in the actual lesions. Original idea of the very first interventions in oncology had favored the necrosis by elevated temperatures in the local area. The original hyperthermia (HT) concept used the consequences of the definite high temperature in the tissue and in the physiology reactions. …”

Szasz O, Andocs G, Gnadig B, Acs B, Szasz A (2011) Booster for all medication processes. Oncothermia Journal 3:54-54

“One of the problematic point of the medication its targeting. The systemically administered drugs are distributed in the whole body by the blood, irrespective its origin by i.v. infusion, orally taken or getting by muscular injection, rectal suppository, skin-addicted, inhalations etc. However the delivery and the in-siut effect of the given drug to the target is a crucial point of the treatment. This is also the main point of the personalization of the drug-administration on every medial actions and especially important in the oncology, where the toxicity is an effective danger….”

Szasz A (2011) Brain glioma results by oncothermia. Oncothermia Journal 3:55-55


None of the established state-of-the-art treatments in malignant primary brain tumors, especially in glioblastoma multiform (GBM), could show effective or commonly accepted curative potential until today. The editorial question of JAMA [1] in 2005 is actual even now: “Where to go from here?” Our objective to show a feasible way to go, summarizing the results obtained till ow made by modulated electro-hyperthermia (oncothermia) in various clinics in EU…”

Pang C (2011) Clifford Hospital – Non-Toxic Integrative Cancer Treatments. Oncothermia Journal 3:56-56

“As a large modern general hospital, Clifford hospital is the first JCI (Joint Commission International) accredited Chinese hospital, a National Grade “Triple-A” Hospital and a “Famous Traditional Chinese Medicine Hospital” of China. It has been accredited by JCI three times. The JCI accreditation surveys are carried out once avery 3 years….”

Meggyeshazi N, Szasz A (2011) Clinical studies and evidences of modulated RF conductive heating (oncothermia) method. Oncothermia Journal 3:57-57


Modulated RF-conductive heating (oncothermia) has twenty years experience in the clinical practices. The presently working more than 100 devices produce enormous number of treatments and collect a strong experience forming a consensus in the treatment. Present a comprehensive summary of clinical studies made by oncothermia. Compare the data and make possible statistically significant statements….”

Rubovszky G, Nagy T, Godeny M, Szasz A, Lang I (2011) Successful co-administration of electrohyperthermia and bevacizumab in non-small cell cancer: A case presentation. Oncothermia Journal 3:58-58


Non-small cell lung cancer (NSCLC) exceeds in number the 85% of all malignant lung cancers. In metastatic disease the principle goal is to prolong survival with the lest toxicity keeping in mind the importance of patients’ quality of life. ...”

Acs B (2011) Development and Designing in Oncotherm Group. Oncothermia Journal 3:59-59

“The current design and devices:
EHY2000, EHY2010, EHY3010
Birth of a new design:

What happens when we start a plan? First of all we talk about what the goal is: a new design, a redesign, a correction on the basis of customer suggestion, etc. When we make a new design, we start with some drafts …”

Saupe H, Buttner C, Andocs G (2011) Oncothermia effect on rouleaux-aggregation of erythrocytes. Oncothermia Journal 3:60-60


Observation and explanation of rouleaux phenomenon induce permanent debate started from its discovery. The aggregation of erythrocytes is a prominent feature in humans and other species “athletic” species [1], in vitro studies have shown that aggregation of blood  increases as shear rate decreases…”


Szasz O, Andocs G, Szasz A (2011) Effects far from equilibrium in electromagnetic heating of tissues. Oncothermia Journal 3:61-61


One of the very first treatment “technologies” for oncology is the regional heating of the tissues and body-parts, (Hyperthermia, HT). This long history was not enough to be accepted as conventional treatment, facing mostly skeptic opinions among the oncology experts. The main reason is its controversial results and poor control, the missing of appropriate selective, controllable safe deep heat-delivery….”


Szasz O, Iluri N, Szasz A (2011) Evaluation of single-arm studies of oncothermia. Oncothermia Journal 3:62-62


Oncothermia survival studies are problematic due to the missing control arm. This is a problem is general, when the treatment targets advanced, mostly refractory, relapsed malignancies in high treatment lines, when the only way is the sequential treatment. Usually the care in high line treatment (or in terminal phase) has very limited evidence based possibilities, its medical decision-making processes are usually well tailored to the individual patients [18], [19]…”


Kim SC, Ju W, Szasz A (2011) History of hyperthermia and electro-treatments. Oncothermia Journal 3:63-63

Our objective to show the long historic development of the hyperthermia and the electromagnetic therapies directly to the present: to the oncothermia.
Ancient approach of heat-therapy

Hyperthermia is ancient treatment. Started with the arly ancient cultures The beginning had sacral & cultural rules, centering on the Sun (like God) in Egyptian philosophy)….”

Feisskohl C, Leckler J, Acs B, Szasz O (2011) History of oncothermia and their devices. Oncothermia Journal 3:64-64


Oncothermia concept was found when the company was established, however the way of realization is a long process, having various steps forward and sometimes dead-ends. Our objective to show the history of oncothermia through its devices, giving a picture how stable development was achieved by the years, and conclude with a lesson how to go further….”

Breitkreutz F (2011) Hyperthermie – Was müssen Krankenkassen und Beihilfe zehlen? Oncothermia Journal 3:65-65

“Einleitung: Nach S 27 Abs. 1 SGB V haben gesetzlich Krankenversicherte einen Anspruch auf Krankenbehandlung, wenn diese notwendig ist, eine Krankheit zu heilen, ihre Verschlimmerung zu verhüten oder Krankheitsbeschwerden zu lindern. Dabei müssen die Qualität und die Wirksamkeit der Leistungen dem allgemein anerkannten Stand der medizinischen Erkenntnisse entsprechen und den medizinischen Fortschritt berücksichtigen (§ 2 Abs. 1 Satz 3 SGB V)….“

Gallne-Vagyi A (2011) Introduction of the international quality management system: Oncotherm Group. Oncothermia Journal 3:66-66

“Common Quality Management System based on:

  • ISO 9001:2008 Quality Management System. Requirements
  • ISO 13485:2003/AC:2009 Medical Devices. Quality Management systems. Requirements for regulatory purposes
93/45 EEC Medical Device Directive (MDD)…”

Balogh L, Andocs G, Thuroczy J, Polyak A, Szasz O, Szasz A (2011) Oncological and non-oncological applications of electromagnetic hyperthermia (Oncothermia®) in the veterinary clinics – 2 years of experience. Oncothermia Journal 3:67-67


Loco-regional hyperthermia in oncology has ambivalence discretion in the medical community. The extremely long history of the method as well as the supposed universal ability to complement all the existing traditional methods is not enough to prove its efficacy. The central point of the non univocal acceptance and the mixed feeling is the some-times unsuccessful selective heat-delivery into the deep-seated tumors….”

Szasz A, Hegyi G, Andocs G, Szasz O (2011) Oncothermia combination with Traditional Chinese Medicine: network approach. Oncothermia Journal 3:68-68


Acupuncure and their connective pathways the meridians are ancient Chinese knowledge but it is not understood yet in details [1]. Request of the stable homeostasis of the complex organisms is demanding interdisciplinary approach and new paradigm for the topic. The detecting and reconstructing the deviation from the normal balance of the homeostasis is the basic principle of TCM….”

Hegyi G, Han B, Li J, Andocs G, Szasz O, Szasz A (2011) Oncothermia combination with Traditional Chinese Medicine: proposal on Chinese herbal medicine approach. Oncothermia Journal 3:69-69


Hyperthermia is an ancient oncology method. It is the very first treatment modality for this type of disease, having 5000 year history [1], based on the Sun as the overall curative force in ancient Egypt. Later Hippocratic paradigm described it using physiological process (acidosis) to eliminate the malignant tissue….”

Szasz A (2011) Oncothermia Concensus. Oncothermia Journal 3:70-70


Oncothermia became a widely used and popular method in over 15 countries of the world. It is not a “gold standard” yet, but it is on the way to reach its stable and important position as a “fourth column” among the main oncotherapy modalities. It has wide-range applicability for every solid tumor in all possible localization, irrespective its primary or metastatic form….”

Woong J, Seung CK (2011) Oncothermia in Gynecologic Oncology. Oncothermia Journal 3:71-71


Ewha Womens Hospital intensively uses oncothermia for gynecological malignancies. The time for the application of the new technology is not enough to present statistically evaluable number of patients in cohorts, so our objective is reporting only an interesting case, having multiple primer metastases…”

Lee DY, Paik HC, Kim JW, Jeon SE, Kim DU (2011) Oncothermia treatment for small-cell-lung carcinoma. Oncothermia Journal 3:72-72


Small cell lung carcinomas (SCLC) were studied combined with various chemotherapies. This is a running study, we present only interim results. Our objective was to obtain reliable data of SCLC treatment with oncothermia…”

Haam SJ (2011) Oncothermia treatment of lung carcinomas. Oncothermia Journal 3:73-73

Advanced lung carcinomas were studied. Oncothermia was combined with various chemotherapies and radiotherapy. Our objective was to obtain was to obtain reliable data of lung-cancer terament with oncohtermia.

Study was started in August 2008, and was sequentially evaluated in December 2009 (n=66) September 2010 (n=118), retrospectively….”

Szasz A, Vincze Gy, Szasz O (2011) Personalization of oncothermia. Oncothermia Journal 3:74-74


Dosing of oncothermia is based on the energy delivery to the targeted tumor [1]. This energy is well focused on cellular level [2], and makes the dose of energy optimal for cell destruction [3]. The personal feedback of the patient is the important control of the process; the patient became the primary sensor of the treatment protocol. This gives good safety records and low toxicity and side effects for the patients, however the objective dose is not equal for them. We know it well, that the dose is an important factor the too low is ineffective, the too high is toxic. Our objective is investigating the personalized feedback in point of view of the objectivity of the dose…”

Skrihar G (2011) Oncothermia research support by LabView-based data-aquision systems. Oncothermia Journal 3:75-75

The necessity of integrated data-acquisition systems

The aim of all scientific experiment and measurement is to collect information about the measured object or incident. On the field of research it’s especially important to acquire all of measurable information during the experiments, because often we don’t know exactly, which of the parameters will give us new and useful informations…”

Szasz O (2011) Success of Oncotherm. Oncothermia Journal 3:76-76


Oncotherm company became this year 21 years old. It has started its life in the Universities. The ideas were formulated as a part of the surface science in Glasgow Scottish Surface Centre, Stratheyde University, followed by a spin-off form the Eotvos University Budapest …”

Feisskohl C, Leckler J (2011) The customer is king: The marketing concept of the Oncotherm Group. Oncothermia Journal 3:77-77

Concept and marketing tools

The focus of our work is informing doctors form all over the world about the method and possibilities of Oncothermia. We are dealing with oncohtermia as a complex method and not simply market and sale of devices…”

Kleff R, Kekic S, Hadcic D, Rigler W, Pecher O (2011) Institute for Hyperthermia und Immunotherapy IWIT, Vienna, 14 Years Experience in locoregional and whole body hyperthermia. Oncothermia Journal 3:78-78

The IWIT ist he leading Institute for Hyperthermia in Austria

  • > 17.000 h of whole body hyperthermia
  • > 5.000 Treatments with locoregional Hyperthermia
Largest center to successfully combine oncological and non-oncological treatments…”